BSECompany Update1d ago · 21 Jul 2026, 02:35 pm
Dear Sir/Madam, Please find the attache statements of investor complaints for the quarter ended 30th June, 2026. You are requested to kindly take the same on record and oblige. Thanking ....
Prism Medico and Pharmacy Ltd · 512217
✦ AI SummaryRegulatory
Prism Medico and Pharmacy Ltd has submitted a report on investor complaints for the quarter ended 30th June, 2026, as per Regulation 13(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The report shows zero pending, received, and disposed-off complaints, with no unresolved complaints at the end of the quarter.
Analysis Scores
Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Prism Medico and Pharmacy Ltd - 512217 - Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
Attachments (1)
📄pdf
Download →
d008ad67-7585-471c-a2a5-ed9dc6d87d90.pdf
View document text
PRISM MEDICO AND PHARMACY SIMITED
CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail. com
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030
Date: 20.07.2026
To, T o,
Department of Corporate Services, Listing Department,
BSE Limited Metropolitan Stock Exchange of India Limited |
P. J. Towers, Dalal Street, (MSE])
Mumbai, Maharashtra-400001. Vibgyor Towers, 4% Floor,
Plot Number C 62, G - Block,
Opposite Trident Hotel,
Bandra Kurla Complex,
ISIN: INE730E01016 Bandra (E), Mumbai, Maharashtra-400098.
Scrip Code: 512217 SYMBOL: PRISMMEDI
Subject: Investor complaints as per Regulation 13(3) of the SEBI (Listing Obligation and
Disclosure Requirements) Regulations, 2015.
Dear Sir / Madam,
With reference to the above captioned subject report on investor complaints for the quarter ended
30% June, 2026 is as follows:
Investor Complaints Number for the Quarter ended 30 June,
2026.
Pending at the beginning of the quarter 0 (Zero)
Received during the quarter 0 (Zero) _
Disposed off during the quarter 0 (Zero)
Remaining unresolved at the end of the quarter 0 (Zero)
You are requested to kindly take the same on your record and acknowledge receipt.
Thanking You.
Yours Truly,
FOR PRISM MEDICO AND PHARMACY LIMITED
DAVENDER SINGH
DIRECTOR
DIN: 09447243.
PURVA SHAREGISTRY (INDIA) PVT. LTD.
9, Shiv Shakti Indl. Estate, J. R. Boricha Marg, Near Lodha Excelus,
Lower Parel (East), Mumbai - 400 011
Tele : 022-4961 4132 / 4970 0138
Web. : www.purvashare.com Email : support@purvashare.com
Ref : 730E/INE730E01016/0626 02/07/2026
PRISM MEDICO & PHARMACY LIMITED
Dear Sir/Madam,
Sub : Statement of Investor Complaints for the Quarter ended 30/06/2026.
Ref.: Scrip Code 512217
In terms of Regulation 13(3) of the SEBI (Listing Obligation and Disclosure
Requirements) Regulations, 2015. Please find herein below the Quarterly Report
on Investor Complaints for the Quarter ended 30/06/2026.
INVESTOR COMPLAINTS
| Pending at the beginning of the quarter | o |
| Received during the quarter | 0
| Disposed off during the quarter | o |
| Remaining unresolved at the end of the quarter | 0
You are requested to kindly take the same on record.
Thanking you,
Yours faithfully,
For PURVA SHAREGISTRY (INDIA) PVT LTD
Ms. Deepali Gaonkar
Compliance Officer
Note: 1) Please include the complaints received directly at your end from the
Regulatory Authorities (BSE/NSE/ROC/SEBI Scores/MSEIL/NSDL/CDSL).
2) Please print this data on Company's Letter Head
3) Please send to "The Manager, Listing Department, The Bombay Stock
Exchange Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001."